Pat Soon-Shiong, Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman at ImmunityBio, and Executive Chairman of the Los Angeles Times, shared a post on X:
“In anticipation of the TV special on NewsNation next week, November 25, Tuesday at 10 pm ET and on Thanksgiving at 9 pm ET, the Cancer Bioshield Protocol is a result of over a decade of clinical trials across multiple tumor types to test and validate the hypothesis that protecting the immune system drives memory T cells.
To achieve this memory in our immune system, it requires a complex orchestration of a therapeutic protocol I drew up as part of the cancer moonshot.
We launched 26 phase 1 and 2 clinical studies, including pancreatic cancer, lung cancer, triple-negative breast cancer, and ten other tumors across over 830 patients receiving over 8,500 doses of ANKTIVA in combination with the therapies outlined in the first drawing to test that this orchestration can be safely given in an outpatient setting. See ClinicalTrials.gov under ‘N-803’.
Complete responses across multiple tumor types and multiple trials were seen and published over the years (2nd image).
Christopher C. Cuomo will try to unravel this complexity in a 1-hour show.
ALC matters. See more details on my X Articles.”
More posts featuring Pat Soon-Shiong.
